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ABSTRACT 50 
Patients with stage 5 chronic kidney disease who are on hemodialysis (HD) remain 51 
in a chronic inflammatory state, characterized by the accumulation of uremic 52 
toxins that induce endothelial damage and cardiovascular disease (CVD). Our aim 53 
was to examine microvesicles (MVs), monocyte subpopulations, and angiopoietins 54 
to identify prognostic markers in HD patients with or without diabetes mellitus 55 
(DM). A total of 160 prevalent HD patients from 10 centers across Spain were 56 
obtained from the Biobank of the Nephrology Renal Network (REDinREN, 57 
Madrid): 80 patients with diabetes mellitus (DM) and 80 patients without DM who 58 
were matched for clinical and demographic criteria. MVs from plasma and several 59 
monocyte subpopulations (CD14++/CD16+, CD14+/CD16++) were analyzed by 60 
flow cytometry, and the plasma concentrations of angiopoietin (Ang)1 and Ang2 61 
were quantified by ELISA. Data on cardiovascular disease were gathered over the 62 
5.5 years after these samples were obtained. MV level, monocyte subpopulations 63 
(CD14+/CD16++ and CD14++/CD16+), and Ang2/Ang1 ratios increased in HD 64 
patients with DM compared with non-DM patients. Moreover, MV level above the 65 
median (264 MVs/µl) were associated independently with greater mortality. MVs, 66 
monocyte subpopulations, and Ang2/Ang1 ratio can be used as predictors for 67 
CVD. In addition, MV level have potential predictive value in the prevention of 68 
CVD in HD patients. These parameters undergo more extensive changes in 69 
patients with DM. 70 
Keywords: chronic kidney disease, cardiovascular disease, diabetes mellitus,  71 
microvesicles, inflammation, hemodialysis 72 
 73 
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INTRODUCTION 74 
Patients with chronic kidney disease (CKD) eliminate toxic compounds from their 75 
body less efficiently, resulting in the accumulation of uremic toxins (8, 14, 52, 54) 76 
and maintenance of a chronic inflammatory state (18, 20, 21, 27, 39). These events 77 
affect endothelial activation and are associated with a higher frequency of 78 
cardiovascular disease (CVD), which is one of the main causes of the high 79 
morbidity and mortality in these patients (29, 42).  80 
Further, in CKD patients, renal failure is related frequently with other diseases, 81 
such as diabetes, that also induce inflammation and endothelial damage (20, 24, 44, 82 
48); the endothelial damage due to diabetes might be another risk factor for CVD 83 
in CKD patients (19, 56). Some studies have examined (1) whether inflammation 84 
and endothelial damage in CKD patients with diabetes differ from endothelial 85 
disease in patients without diabetes and have identified markers of inflammation 86 
and endothelial damage in CKD. 87 
The inflammatory state is associated with the activation and apoptosis of 88 
endothelial cells (ECs), leading to the release of recently identified circulating 89 
biomarkers that are related to endothelial dysfunction, called CD31+Annexin V+ 90 
microvesicles (MVs) (5, 43), which have been proposed to be markers of 91 
endothelial damage and dysfunction in several pathologies (15, 17, 26).  92 
Extracellular vesicles (EVs), including exosomes (<100 nm) and microvesicles (100-93 
1000 nm), are small secreted membrane-enclosed entities that are involved in 94 
various biological, physiological, and pathological phenomena. In our study we will 95 
use the term MVs as our EV detection method allows detection of mostly larger 96 
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EVs (>400nm). EVs protect a wide range of biomolecules that originate from 97 
secreting cells and their molecular cargo changes in diseases and other 98 
physiological states (25, 34, 58). In conventional flow cytometry, the range of 99 
detection of microvesicles is 400-1000 nm (38). During inflammation, the number 100 
of EVs increases (22, 53). The effects of EVs might be mediated by their support of 101 
cell-to-cell crosstalk, because EVs transport microRNA, active molecules, 102 
hormones, peptides, and regulator proteins (6, 16, 35), the levels of which rise in 103 
patients with CVD, CKD, and type II diabetes mellitus (T2DM) (23, 50). Further, 104 
proinflammatory monocytes (CD14+/CD16++) (3, 10, 36, 60, 61) and monocytes 105 
that predict cardiovascular risk (CD16++/CD14+) (22, 47, 60, 61) are elevated in 106 
the peripheral blood of patients with CVD. These data have been confirmed in 107 
CKD patients, and we have reported that the amounts of these proinflammatory 108 
cells correlate with various markers of endothelial damage, including MVs (36, 109 
43). 110 
Angiopoietin 1 (Ang1) stabilizes the endothelium by inhibiting endothelial cell 111 
apoptosis and activation and decreasing inflammation. In contrast, angiopoietin 2 112 
(Ang2) is proinflammatory and promotes endothelial and epithelial cell apoptosis, 113 
increases neutrophil adhesion, and induces cytoskeletal changes to widen 114 
interendothelial gaps. The ratio of Ang-2 to Ang-1 might be a useful prognostic 115 
biomarker of endothelial activation (40). 116 
Based on the frequency of cardiovascular complications in patients with stage 5 117 
CKD who are on hemodialysis (HD), we must improve our understanding of the 118 
development of endothelial damage to identify markers that can predict the 119 
progression of CVD and establish appropriate targets that might delay disease 120 
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progression. Therefore, our goal of was to measure MV level, monocyte 121 
subpopulations, and other soluble markers of endothelial damage, such as 122 
angiopoietins, in patients with and without diabetes to determine whether these 123 
markers identify CVD patients with HD, whether diabetes modifies their 124 
expression profiles in HD, and whether they are prognostic markers in HD 125 
patients with and without diabetes. 126 
MATERIAL AND METHODS 127 
Research participants 128 
Samples from 160 patients on HD were obtained from the Biobank of the 129 
Nephrology Renal Network (REDinREN, Madrid) from a total population of 400 130 
HD patients from whom samples had been collected. The patients underwent HD 131 
in various dialysis units throughout Spain. Blood samples were obtained just 132 
before the HD session began. The bacterial and endotoxin contamination levels 133 
were below the detection limit in all premixed dialysate samples (<1 bacterial 134 
colony-forming unit/ml and <0.03 endotoxin units).  135 
Data were also gathered on parameters that were related to severe CVD, defined 136 
as a cardiovascular event, acute myocardial infarction (AMI), cerebrovascular 137 
accident (CVA), or transient ischemic attack (TIA), until completion of the study 138 
(5.5 years).  139 
The study was approved by the Biobank Ethics Committee, and all subjects 140 
provided written informed consent prior to collection of the samples and their 141 
storage in the biobank. 142 
Characteristics of the study population 143 
7 
 
The algorithm that we used to select patients is shown in Figure 1. Of the 118 HD 144 
patients with DM, we chose 80 HD patients (18 HD T1DM patients and 63 HD 145 
T2DM patients) who had undergone at least 6 months of HD and did not have a 146 
history of cardiovascular events. Then, we selected 80 HD patients without DM 147 
who were matched for center (rate 1:1) and demographics (similar percentage of 148 
men and those aged older than 50 years). The mean age of the study population 149 
(n=160) was 64.23 ± 3.88 years, and the study sample comprised 95 men and 65 150 
women (Table 1). No differences in CRP levels were observed. Fifteen healthy 151 
subjects (50% men, 25% smoking, no hypertension, no hyperlipidemia) were 152 
included as controls. Blood samples were drawn from the arterial line before the 153 
start of HD or by venipuncture in healthy individuals. For this a 21 gauge needle 154 
was used (57). 155 
Isolation and determination of  MVs in plasma 156 
Platelet-free plasma was obtained by centrifugation at 1500 g for 20 min at room 157 
temperature. Next, the supernatant was recovered and centrifuged at 13,000 g for 158 
2 min to separate MVs. The supernatant was discarded and the pellets were stored 159 
at -80ºC until use (28, 31, 46, 57). MVs were then resuspended and incubated with 160 
5 µl of phycoerythrin (PE)-labeled monoclonal anti-CD31 (Caltag Laboratories, 161 
Burlingame, CA, USA) using fluorescein isothiocyanate-conjugated (FITC) 162 
annexin V kits per the manufacturer’s instructions (Bender MedSystem, Vienna, 163 
Austria). CD31 is an adhesion molecule that identifies EVs that are derived from 164 
ECs, platelets, and leukocytes. MVs that expressed phosphatidylserine were 165 
labeled using fluorescein-conjugated Annexin V solution in the presence of CaCl2 166 
(5 mM) per the supplier. As a control for the Annexin V labeling, a sample with 167 
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fluorescein-conjugated Annexin V using a CaCl2-free solution was established. 168 
Isotype controls were included as negative controls for the CD31 labeling. An 169 
equal volume of Flow Count Calibrator beads (Beckman Coulter Inc, Fullerton, 170 
CA, US) was added to measure the number of events per microliter. Fluorescence-171 
activated cell sorter analysis was performed on a Coulter Cytomic FC 500 flow 172 
cytometer (Beckman Coulter Inc, Fullerton, CA, US) using CXP (Beckman 173 
Coulter).  174 
Prior to the sample acquisition, the samples were subjected to a separate and 175 
combined labeling reaction using all reactives (monoclonal antibodies, Annexin V, 176 
and the appropriate negative controls) to compensate for the fluorescence using 177 
compensation tools on the flow cytometer. A MVs gates was established on the FC 178 
500 in preliminary standardization experiments using a blend of size-calibrated 179 
beads (Beckman Coulter Inc, Fullerton, CA, US) with diameters of 0.3 µm, 0.5 µm, 180 
and 1.0 µm. The upper and outer limits of the MVs gate were established just 181 
above the size distribution of the 1-µm beads in the forward (FSC-A) and side 182 
scatter (SSC-A) settings (log scale). The lower limit was the noise threshold of the 183 
instrument (SSC-A), limiting high background noise. The absolute number of MVs 184 
was calculated as: (MVs counted x standard beads/L)/standard beads counted 185 
(FlowCount, Beckman Coulter). Each result (single value) was the average of 3 186 
independent measurements of the same sample.  187 
Monocyte subpopulations 188 
A 10-mL sample of peripheral blood was drawn from HD patients and healthy 189 
subjects into tubes that contained ethylenediaminetetraacetic acid (EDTA) and 190 
deposited into the biobank. Peripheral blood mononuclear cells (PBMCs) were 191 
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isolated by Ficoll density-gradient centrifugation (Lymphoprep, Axis-Shield PoC 192 
AS, Oslo, Norway), washed with PBS (GIBCO, Invitrogen, Carlsbad, BA), and 193 
supplied with 20% fetal bovine serum (FBS, GIBCO, Invitrogen). After 194 
separation, PBMCs were frozen in FBS with 10% DMSO at -80ºC for 24 h and 195 
transferred to liquid nitrogen until the day of processing. The suitability of the 196 
samples for processing and labeling was verified using parallel unfrozen control 197 
blood. Cell viability was tested by mixing cell suspensions with trypan blue solution 198 
(25900048R, CORNING Cellgro, Manassas, VA 20109, USA). 199 
To identify CD14+/CD16++ and CD14++/CD16+ monocytes, PBMCs were 200 
incubated with peridinin chlorophyll protein (PerCP)-conjugated monoclonal anti-201 
CD14 (M5E2) and FITC-conjugated anti-CD16 (3G8). Both antibodies and the 202 
appropriate isotype controls were purchased from Becton Dickinson (BD 203 
Biosciences; San Jose, CA, USA). Flow cytometry was performed on a 204 
FACSCalibur (BD Biosciences) using Cell Quest. The percentage of 205 
CD14+/CD16++ and CD14++/CD16+ monocytes was calculated by subtracting 206 
nonspecifically stained cells, as identified in the isotype control histogram.  207 
Angiogenic factors 208 
The soluble angiogenic factors Ang-1 and Ang-2 were quantified by ELISA (R&D 209 
Systems, Minneapolis, Minnesota) per the manufacturer's instructions.  210 
Statistical analysis 211 
Continuous data were expressed as mean ± standard deviation (SD) and as the 212 
median (Q1, Q3) for normal and skewed distributions, respectively. Comparisons 213 
between means of healthy subjects versus HD non-DM, HD 1TDM, and HD 2TDM 214 
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were analyzed by ANOVA, followed by Duncan test. Chi-squared test was used for 215 
categorical data. Categorical data were expressed as percentages. Survival of HD 216 
non-DM and HD DM patients was analyzed by Kaplan-Meier method, and 217 
differences in survival between 2 or more groups were examined by log-rank test, 218 
from the collection of blood samples to the start of the follow-up. The influence of 219 
MVs on patient survival after stratification by DM or non-DM was analyzed as a 220 
categorical variable—divided in 2 groups (above or below the median value)—and 221 
adjusted using traditional cardiovascular risk factors (smoking, hypertension, and 222 
hyperlipidemia) by multivariable Cox regression. 223 
Correlation analysis was performed between the study variables (CD14++/CD16+, 224 
CD14+/CD16++, and MVs) in each group (HD non-DM, HD DM) separately by 225 
Pearson or Spearman test where appropriate. All statistical analyses were 226 
performed with SPSS 15.0. Two-sided P values of less than 0.05 were considered to 227 
be statistically significant. 228 
RESULTS 229 
Quantification of MV level (MVs/ µl) in HD patients 230 
Representative graphs of the flow cytometry analysis of EVs and the number of 231 
MVs in HD patients are shown in Figure 2 A and B. Size-selected events plotted as 232 
a function of their double fluorescence for specific annexin-phycoerythrin (PE) 233 
binding and CD31-FITC, negative control (C) and HD patients (D).We observed 234 
that HD non-DM patients experienced a significant increase in MV level 235 
(236.4±20.8 MVs/µl) in relation to healthy subjects (26.9±4.1  MVs/µl; p<0.001). 236 
Similarly, HD patients with T1DM had significantly higher MV level (259.0±34.3) 237 
11 
 
versus healthy subjects (26.9±4.1 MVs/µl; p<0.001). HD patients with T2DM had 238 
significantly more MVs (321.9 ± 33.5 MVs/µl) compared with healthy subjects 239 
(26.9±4.1 MVs/µl; p<0.001). Moreover, T2DM subjects had higher MV level than 240 
HD patients without DM (321.9 ± 33.5 MVs/µl vs 236.4 ± 20.8 MVs/µl, p=0.014) 241 
(Figure 2E). 242 
Monocyte subpopulations in HD patients 243 
The percentage of CD14+/CD16++ monocytes defines the extent of inflammation, 244 
which we calculated by flow cytometry (Figure 3A-C). The percentage of 245 
CD14+/CD16++ monocytes was higher in HD non-DM (8.4 ± 3.5%) and T1DM 246 
patients (11.6 ± 3.4%) than in healthy subjects (2.8± 0.9%, p<0.001). Further, the 247 
percentage of CD14+/CD16++ monocytes was elevated in T1DM patients (11.6 ± 248 
3.4%) compared with HD non-DM (8.4 ± 3.5%, p=0.001) and T2DM subjects (5.8 249 
±1.8%, p<0.001) (Figure 3D). 250 
The percentage of CD14++/CD16+ monocytes was associated with higher rates of 251 
cardiovascular events. Also, this percentage was significantly higher in T1DM 252 
versus healthy (5.1 ± 1.1% vs 3.1 ± 0.8%, p=0.009) and HD without DM patients 253 
(4.3 ± 2.3%, p=0.043) (Figure 3E). 254 
Ang2/Ang1 ratio in HD patients 255 
The Ang2/Ang1 ratio was calculated in plasma samples from healthy subjects and 256 
patients with HD. HD patients without DM had an Ang2/Ang1 ratio of 8.2±4.5, 257 
which was significantly higher than in healthy subjects (0.5 ± 0.1, p<0.001). HD 258 
patients with T1DM had significantly higher Ang2/Ang1 ratios (2.9±2.5) than 259 
healthy subjects (0.5±0.1, p<0.001). Moreover, HD patients with T2DM had 260 
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significantly higher Ang2/Ang1 ratios (9.3±5.4) compared with healthy subjects 261 
(0.5±0.1, p<0.001) (Figure 4A).  262 
Correlation between inflammation and endothelial damage 263 
In HD patients, we observed a positive correlation between the percentages of 264 
CD14++/CD16+ and CD14+/CD16++ monocytes (rho correlation Spearman = 265 
0.544, p = <0.001) (Figure 5A), which also existed in HD patients with DM and in 266 
those without DM (rho correlation Spearman = 0.428, p = 0.05 for patients with 267 
DM; rho correlation Spearman = 0.599, p <0.001 in patients without DM). 268 
MV level and the percentage of CD14+/CD16++ monocytes correlated in HD 269 
patients (Spearman rho correlation = 0.348, p = 0.017) (Figure 5B) (Table 2). 270 
Mortality in HD patients with and without DM vs MV level 271 
We analyzed the relationship between MV level and mortality in HD patients with 272 
and without DM after a median of 5.5 years of follow-up by Kaplan-Meier method. 273 
The patients were divided into 2 groups, defined by the median level of MVs. HD 274 
patients with MV level ≤264 MVs /µl had improved survival versus those with 275 
levels that were above the median (log-rank<0.001) (Figure 6A). HD patients 276 
without DM with MV level ≤264 MVs /µl had greater survival than those with 277 
higher-than-median levels (log-rank <0.001) (Figure 6B). HD patients with DM 278 
and MV level ≤264 MVs /µl also survived longer than patients with MV level that 279 
exceeded the median (log-rank=0.023) (Figure 6C). 280 
Ang2/Ang1 ratio and the CD14+/CD16++ and CD14++/CD16+ subpopulation 281 
percentages were not associated with mortality.  282 
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Cox regression analysis 283 
The hazard ratio for death in HD patients after adjustments by DM and non-DM 284 
increased significantly among patients with higher levels of MVs (MVs >264, 285 
2.364; 95% confidence interval [CI], 1.395 to 4.008; P=0.001). The hazard ratio 286 
remained significantly higher after adjustments for traditional cardiovascular risk 287 
factors (smoking, hypertension, and hyperlipidemia). 288 
DISCUSSION 289 
In this study, we analyzed factors that are related to endothelial damage in 290 
patients with                                                                                                                                                                                                                                                                                                                                                                         291 
HD. Plasma from these patients contained more MVs and had higher Ang2/Ang1 292 
ratios compared with healthy subjects. The extent of endothelial damage was worst 293 
in diabetic patients. In contrast to healthy subjects, HD patients experienced an 294 
increase in the percentage of proinflammatory (CD14+/CD16++) and high-295 
cardiovascular-risk (CD14++/CD16+) monocyte subsets.  296 
Parameters of morbidity and mortality were recorded for up to 5.5 years. MV level 297 
were associated with mortality in HD patients with and without DM. The rise in 298 
CD14+/CD16++ cells was proportional to the CD14++/CD16+ monocyte 299 
percentage and MV level.  300 
As described (37), patients on HD harbor more MVs than healthy subjects. MV 301 
level are also higher in other disease states, such as hypertension,  diabetes mellitus 302 
and coronary artery disease (9). Consistent with previous results, we noted that 303 
patients with HD and DM had higher MV level than non-DM HD patients, and 304 
these levels affected T1DM as much as they did T2DM (39,41). MV level have 305 
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potential value in the diagnosis and therapeutic management of cardiovascular 306 
disease and might indicate worse endothelial damage in HD DM. In patients with 307 
coronary heart disease, the number of MVs that bind to annexin V predicts 308 
myocardial infarction and mortality (33). In this regard, we have found an 309 
association between the number of MVs and mortality in HD patients. In addition, 310 
we have observed that patients with and without DM with MV level ≤264 MVs /µl 311 
experience greater survival than those with MV level >264 MVs /µl.  312 
In earlier studies, we reported that HD patients have a high percentage of 313 
proinflammatory CD14+/CD16++ monocytes (35, 43, 45). These cells have been 314 
postulated to mediate the ongoing inflammation in such patients, secreting more 315 
proinflammatory cytokines than CD14++/CD16- cells (45). Further, 316 
CD14+/CD16++ monocytes are associated with chronic inflammatory conditions 317 
and have significant function in the development of DM (41). In our study, patients 318 
with HD had a higher percentage of CD14+/CD16++ monocytes than healthy 319 
subjects. There is evidence that circulating monocytes in patients with T1DM can 320 
be induced to secrete proinflammatory cytokines (7). We also observed an increase 321 
in these proinflammatory monocytes in HD patients with DM, the percentage of 322 
which depends on whether the diabetes is T1 or T2. Patients with T1DM had a 323 
higher percentage of CD14+/CD16++ monocytes than those with T2DM.  324 
HD patients had a higher percentage of monocytes that predict cardiovascular risk 325 
(CD14++/CD16+) compared with healthy subjects. These monocyte populations 326 
are elevated in patients with HD (32, 51). We found that patients with HD and DM 327 
also had a greater percentage of CD14++/CD16+ than HD patients without DM, 328 
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indicating that patients with DM have an increased risk of developing 329 
cardiovascular disease. 330 
The imbalance in Ang 1 and Ang 2 levels is related to diabetes, cardiovascular 331 
disease, and tumorigenesis (2, 13, 30), and the Ang2/Ang1 ratio might be an early 332 
marker of endothelial dysfunction (12, 55). In our study, patients with HD 333 
experienced an imbalance in the levels of angiopoietins. Further, the Ang2/Ang1 334 
ratio increased in patients with DM compared with healthy subjects. However, 335 
these values  had no predictive value with regard to mortality. 336 
Our study showed that the levels of CD14+/CD16++ and CD14++/CD16+ 337 
monocytes rose significantly in HD patients. Both subsets correlated positively, and 338 
it is possible that both have important functions in inflammation and CVD. 339 
Nevertheless, this association was not significant in HD DM patients, although it 340 
appeared to have a relative tendency. We can not explain this disparate correlation 341 
between monocyte subsets in HD-DM compared with HD patients. Thus, future 342 
studies should establish the events that occur in DM that might be implicated in 343 
the changes in monocyte subpopulations. Consequently, the rise in the number of 344 
these cells in CKD patients might mediate the development of vascular disease, 345 
even though the mechanisms should be examined. Moreover, our studies showed 346 
an association between MVs and CD14+/CD16++ monocytes in HD patients, which 347 
explain the chronic inflammatory status of these patients.  348 
The major limitation of our study is that patients with HD had a high risk of 349 
mortality due to CVD, some of whom could have been lost during the study period. 350 
Further, despite being a multicenter study, it was performed in a small sample of 351 
patients, necessitating larger prospective studies.  352 
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The prevalence of CVD is higher in HD patients with DM and elderly patients (>50 353 
years), which has significant clinical relevance but is another limitation of our 354 
study. We would also be interested in studying younger patients and patients in a 355 
less advanced stage of CKD to identify early markers of the disease. Moreover, we 356 
cannot exclude that the differences between T1DM and T2DM are attributed to 357 
disparities in glycemic control, which would have an impact on the parameter that 358 
is assessed.  359 
The size detection limits of standard flow cytometry are well known, causing 360 
smaller MVs to be overlooked. Upper size limit of EV detection is likely >1µm, as a 361 
0.5 µm polystyrene bead is reflecting already an EV around 1 µm  (11) . 362 
Consequently, absolute MV count might be underrepresented. Isolation, 363 
purification, identification, and conservation protocols for EVs have advanced 364 
significantly. We also believe that MV population might be contaminated with EVs 365 
from other origins, such as platelets. Moreover, annexin V binding by MVs is a 366 
calcium-dependent process, and this marker has limited value in assessing 367 
apoptotic MVs. However, annexin V+ MVs remain a well-studied marker of 368 
apoptosis-derived MVs from peripheral blood in healthy individuals and HD 369 
patients (4). 370 
The results of our study have significant multidisciplinary implications for a wide 371 
range of areas in biomedicine, examining a problem that is a component of many 372 
chronic conditions. The resulting increase in our understanding of MVs, monocyte 373 
subpopulations, and angiogenic factors in CVD can guide the diagnosis and 374 
prognosis of the disease and the design of novel drug therapies. In addition, MVs 375 
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from platelets and leukocytes might also be involved in inflammation, prompting 376 
future studies. 377 
There is no consensus on how to detect and preserve MVs. In addition, no single 378 
method can characterize these vesicles completely (phenotype, size, count, and 379 
image). MVs abound in body fluids, and the detection of MVs in suspension by 380 
flow cytometry has attracted strong clinical and scientific interest, but their 381 
detection is difficult, because many MVs are small (<400 nm), below the limit of 382 
resolution of a most flow cytometers, causing valuable information on their 383 
characteristics to be lost. Other methods (nanoparticle tracking analysis, electron 384 
microscopy, resistive pulse sensing) are thus being used to complement flow 385 
cytometry (53, 59). Currently, the major challenge for flow cytometry is the 386 
identification of single vesicles with a diameter that is less than the present limit of 387 
detection. 388 
In conclusion, our findings confirm that patients with HD remain in an 389 
inflammatory state and undergo endothelial alterations that can be tracked using 390 
early quantifiable markers in peripheral blood. Notably, MVs, measuring 400-391 
1000 nm, have potential predictive value in the prevention of cardiovascular 392 
disease in patients with HD. In addition, diabetes mellitus alters these 393 
inflammatory and endothelial damage factors. 394 
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  Table 1. Clinical characteristics of HD patients 615 
  
Healthy 
subjetcs 
Non-DM 1TDM 2TDM P value 
 n=15 n = 80 n=18 n = 62  
Men, n (%) 8 (53.3) 50 (62.5) 9 (50.0) 45 (56.2) 0.8 
eKt/V, mean±SD  1.6±0.3 1.5±0.2 1.5±0.3 0.8 
PCR, median(Q1, Q3) 
(mg/dl) 
 
2.9(1, 9) 
4.1(1.3,8.9) 
4(1.1, 10.7) 
0.6 
Smoking     0.9 
YES, n (%) 4 (26.6) 33 (41.2) 6 (33.4) 25 (40.4)  
NO, n (%) 11 (73.4) 47 (58.8) 12 (66.6) 37 (59.6)  
Hypertension, n (%) 0 47 (58.8) 13 (72.3) 45 (72.5) 0.2 
Hyperlipidemia, n (%) 0 41 (51.2) 11 (61.5) 43 (69.3) 0.1 
HD modality (% online 
hemodiafiltration) 
0 12.5 10.5 16 0.9 
HD modality (% low-flux 
hemodialysis) 
0 40 55.5 35 0.6 
HD modality (% high-flux 
hemodialysis) 
0 47.5 30 49 0.65 
Unknown HD modality (%)  0 4  0 
CVD       0.04 
YES, n (%) 0 21 (26.2) 7 (38.9) 29 (46.7)  
NO, n (%) 0 (100) 59 (73.7) 11 (61.1) 33 (53.3)  
      
 616 
 617 
 618 
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Table 2. Correlation analysis 619 
 Non DM DM HD 
Correlation p value Correlation p value Correlation p value 
MVs vs Ang2/Ang1 
MVs vs CD14+/CD16++ 
MVs vs CD14++/CD16+ 
Ang2/ang1 vs CD14+/CD16++ 
Ang2/ang1 vs CD14+/CD16+ 
CD14+/CD16++ vs 
CD14++/CD16+ 
-0.110 
0.238 
0.091 
- 0.172 
-0.227 
0.599 
0.4 
0.1 
0.6 
0.4 
0.3 
<0.001 
-0.005 
0.428 
0.211 
0.107 
0.307 
0.428 
0.9 
0.07 
0.4 
0.7 
0.2 
0.05 
-0.082 
0.348 
0.258 
-0.165 
0.018 
0.544 
0.4 
0.02 
0.08 
0.3 
0.9 
<0.001 
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LEGENDS TO FIGURES 620 
Figure 1: Patient flowchart for selection of study population, with inclusion and 621 
exclusion criteria. 622 
Figure 2: Quantification of MVs in plasma of HD patients. Fluorescence-gated 623 
beads of various sizes for determining gates between 0.4 µm to 1 µm (A). 624 
Representative graphs of flow cytometry analysis of EVs in platelet-free plasma. 625 
EVs were plotted using forward scatter logarithmic (FS/log)/side scatter 626 
logarithmic (SS-log) dot plot histogram. MVs are defined as event numbers with a 627 
size of 0.4-1 µm and are gated in a window. It was necessary to use bead counts in 628 
each experiment to calculate the concentration of MVs per unit volume of the 629 
sample (B). Size-selected events plotted as a function of their double fluorescence 630 
for specific annexin-phycoerythrin (PE) binding and CD31-FITC, negative control 631 
(C) and HD patients (D).  Number of MVs /µl in healthy patients with HD patients 632 
no DM, T1DM, and T2DM (E). *p<0.001 vs control; #p=0.014 vs non-DM 633 
(ANOVA, followed by Duncan test).  634 
 Figure 3: Representative flow cytometry of monocyte subsets. Backgated (R1-635 
monocytic gate) within the FCS height/SSC height (A). The monocyte subsets (M1: 636 
CD14++/CD16-; M2: CD14++/CD16+; M3: CD14+/CD16++) within the population 637 
were assessed using anti-CD16-FITC/anti-CD14-PerCP dot plot control (B) and 638 
HD patients (C). Percentage of CD14+/CD16 ++ monocytes in healthy subsets and 639 
non-DM, T1DM, and T2DM patients (D). *p<0.001 vs control; #p=0.001 vs non-640 
DM; and p<0.001 vs T1DM. Percentage of CD14+/CD16 ++ monocytes in healthy 641 
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subsets and non-DM, T1DM, and T2DM patients (E). *p=0.009 vs control; 642 
#p=0.043 vs T1DM (ANOVA, followed by Duncan test). 643 
Figure 4: Ang2/Ang1 ratio in HD patients. Ang2/Ang1 ratio healthy patients with 644 
HD patients without DM and with T1DM and T2DM (A). *p0=0.001 vs control 645 
(ANOVA, followed by Duncan test). Ang 1 and 2 were quantified by ELISA in 646 
plasma (pg/ml).  647 
Figure 5: Correlation between CD14++/CD16+ and CD14+/CD16++ monocytes in 648 
HD patients (A). Correlation between CD14+/CD16++ monocytes and MVs in HD 649 
patients (B). 650 
Figure 6: Kaplan-Meier survival curves with regard to MV level (median) over 5.5 651 
years. HD patients (6A). HD patients without DM (6B). HD patients with DM (6C). 652 
 653 
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